Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma.
We describe a patient with highly refractory malignant lymphoma who died of hepatic tumor rupture following treatment with irinotecan (CPT-11). This 60-year-old man with non-Hodgkin's lymphoma (diffuse large B-cell lymphoma) demonstrated disease recurrence in the liver and the vertebrae following high-dose chemotherapy and autologous hematopoietic stem cell transfusion. He was treated with CPT-11 at a dose of one third of the conventional dose used for non-Hodgkin's lymphoma in Japan. The tumor in the liver markedly decreased in size but then ruptured. Although pathologic hepatic tumor rupture is a rare complication in patients with malignant lymphoma of the liver, this case demonstrates that hepatic tumor rupture may occur in refractory malignant lymphomas that reveal extensive degradation by this new, effective salvage therapy.
Tsutani
H
H
First Department of Internal Medicine, Fukui Medical University, School of Medicine, Japan. htsutani@fmsrsa.fukui-med.ac.jp
Inai
K
K
Kishi
S
S
Morinaga
K
K
Naiki
H
H
Ueda
T
T
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D000077146:Irinotecan; D008099:Liver / Q000473:pathology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012421:Rupture / Q000139:chemically induced; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin